Plus   Neg

Cellectar Biosciences Skyrockets On Positive Data In Cancer Trial

Clinical stage biopharmaceutical company Cellectar Biosciences (CLRB), said a patient with a rare type of cancer that begins in the white blood cells, showed a 94% reduction in tumor burden and complete resolution in four of five targeted tumor masses, in a mid-stage cancer study. CLRB is currently trading up 1365.95% at $10.98.

Key takeaways from the company's Press Release

* Prior to study enrollment, this 67-year-old female patient was diagnosed with Waldenstrom macroglobulinemia (a rare type of cancer that begins in the white blood cells) had received two lines of multi-drug therapy with the most recent treatment achieving a best response of disease progression

*As part of Cellectar's Phase 2 study in hematologic cancers, the patient received a single 25mCi/m2 dose of the company's investigational drug CLR 131 over a 30-minute infusion period. On day 52 post infusion, a CT scan showed a >50% reduction in tumor volume and was classified as a partial response.

*Based on this initial response and additional clinical factors, the treating physician administered a second dose of CLR 131 on day 123. A CT scan taken 64 days after the second dose, showed a 94% overall reduction in tumor burden and complete resolution in four of five targeted tumor masses. The total targeted tumor mass shrank from approximately 4700mm2 prior to the first CLR 131 infusion to approximately 500mm2 at last reading.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Global PC shipments returned to growth in the second quarter of 2020 after seeing a significant decline in the preceding first quarter due to COVID-19 related supply-chain disruptions, according to reports by two research firms. The PC market returned to growth in the quarter as production ramped up and vendors restocked their supplies to near-normal levels. The bankruptcy filing of America's oldest apparel retailer Brooks Brothers has ignited significant interest from potential buyers for the brand. WHP Global and a venture backed by Authentic Brands Group LLC and Simon Property Group, Inc., are reportedly considering bids for the retailer. WHP Global owns the ANNE KLEIN and JOSEPH ABBOUD brands. Sundial Herbal Products has recalled around 65 products, which were misbranded and currently unapproved drugs, the U.S. Food and Drug Administration said in a statement. The recall follows an order by a federal judge in June to stop distributing the company's unapproved new drugs. The affected items include herbal products and dietary supplements.
Follow RTT